Home » Lung Cancer Diagnostic Tests Market
Lung Cancer Diagnostic Tests Market
Published date: Aug 2022 •Formats:
Request Sample Schedule a Call

Global Lung Cancer Diagnostic Tests Market By Type (Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, Circulating Tumor Cells, Pharmacodiagnostics, and Biomarkers Diagnostics Methods), By Application (Precision Medicine, Personalized Medicine, and Cancer Monitoring), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028

  • Published date: Aug 2022
  • Report ID: 41429
  • Number of Pages: 234
  • Format:
  • keyboard_arrow_up
    • 1. Lung Cancer Diagnostic Tests Market Introduction
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
    • 2. Executive Summary
      • 2.1. Key Findings by Major Segments
      • 2.2. Top strategies by Major Players
    • 3. Global Lung Cancer Diagnostic Tests Market Overview
      • 3.1. Lung Cancer Diagnostic Tests Market Dynamics
        • 3.1.1. Drivers
        • 3.1.2. Opportunities
        • 3.1.3. Restraints
        • 3.1.4. Challenges
      • 3.2. PESTLE Analysis
      • 3.3. Opportunity Map Analysis
      • 3.4. PORTER'S Five Forces Analysis
      • 3.5. Market Competition Scenario Analysis
      • 3.6. Product Life Cycle Analysis
      • 3.7. Opportunity Orbits
      • 3.8. Production Analysis by Region/Company
      • 3.9. Industry chain Analysis
      • 3.10. Marketing Strategy
    • 4. Global Lung Cancer Diagnostic Tests Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
      • 4.1. Global Lung Cancer Diagnostic Tests Market Analysis by Type: Introduction
      • 4.2. Market Size and Forecast by Region
      • 4.3. Immunoassays
      • 4.4. Flow Cytometry
      • 4.5. Rapid Tests
      • 4.6. Molecular Assays
      • 4.7. Tissue Arrays
      • 4.8. Circulating Tumor Cells
      • 4.9. Pharmacodiagnostics
      • 4.10. Biomarkers Diagnostics Methods
    • 5. Global Lung Cancer Diagnostic Tests Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
      • 5.1. Global Lung Cancer Diagnostic Tests Market Analysis by Application: Introduction
      • 5.2. Market Size and Forecast by Region
      • 5.3. Precision Medicine
      • 5.4. Personalized Medicine
      • 5.5. Cancer Monitoring
    • 6. Global Lung Cancer Diagnostic Tests Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
      • 6.1. North America
        • 6.1.1. North America Lung Cancer Diagnostic Tests Market: Regional Trend Analysis
          • 6.1.1.1. US
          • 6.1.1.2. Canada
          • 6.1.1.3. Mexico
      • 6.2.1. Europe
        • 6.2.1. Europe Lung Cancer Diagnostic Tests Market: Regional Trend Analysis
          • 6.2.1.1. Germany
          • 6.2.1.2. France
          • 6.2.1.3. UK
          • 6.2.1.4. Russia
          • 6.2.1.5. Italy
          • 6.2.1.6. Spain
          • 6.2.1.7. Rest of Europe
      • 6.3. Asia-Pacific
        • 6.3.1. Asia-Pacific Lung Cancer Diagnostic Tests Market: Regional Trend Analysis
          • 6.3.1.1. China
          • 6.3.1.2. Japan
          • 6.3.1.3. Korea
          • 6.3.1.4. India
          • 6.3.1.5. Rest of Asia-Pacific
      • 6.4. Latin America
        • 6.4.1. Latin America Lung Cancer Diagnostic Tests Market: Regional Trend Analysis
          • 6.4.1.1. Brazil
          • 6.4.1.2. Argentina
          • 6.4.1.3. Rest of Latin America
      • 6.5. Middle East and Africa
        • 6.5.1. Middle East and Africa Lung Cancer Diagnostic Tests Market: Regional Trend Analysis
          • 6.5.1.1. GCC
          • 6.5.1.2. South Africa
          • 6.5.1.3. Israel
          • 6.5.1.4. Rest of MEA
    • 7. Global Lung Cancer Diagnostic Tests Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 7.1. Market Share Analysis
      • 7.2. Company Profiles
      • 7.3. Advpharma Inc
        • 7.3.1. Company Overview
        • 7.3.2. Financial Highlights
        • 7.3.3. Product Portfolio
        • 7.3.4. SWOT Analysis
        • 7.3.5. Key Strategies and Developments
      • 7.4. AIT Austrian Institute of Technology GmbH
        • 7.4.1. Company Overview
        • 7.4.2. Financial Highlights
        • 7.4.3. Product Portfolio
        • 7.4.4. SWOT Analysis
        • 7.4.5. Key Strategies and Developments
      • 7.5. Courtagen Life Sciences Inc
        • 7.5.1. Company Overview
        • 7.5.2. Financial Highlights
        • 7.5.3. Product Portfolio
        • 7.5.4. SWOT Analysis
        • 7.5.5. Key Strategies and Developments
      • 7.6. DiagnoCure Inc. (Inactive)
        • 7.6.1. Company Overview
        • 7.6.2. Financial Highlights
        • 7.6.3. Product Portfolio
        • 7.6.4. SWOT Analysis
        • 7.6.5. Key Strategies and Developments
      • 7.7. BioMark Diagnostics Inc.
        • 7.7.1. Company Overview
        • 7.7.2. Financial Highlights
        • 7.7.3. Product Portfolio
        • 7.7.4. SWOT Analysis
        • 7.7.5. Key Strategies and Developments
      • 7.8. BioMarker Strategies LLC
        • 7.8.1. Company Overview
        • 7.8.2. Financial Highlights
        • 7.8.3. Product Portfolio
        • 7.8.4. SWOT Analysis
        • 7.8.5. Key Strategies and Developments
      • 7.9. Emory University
        • 7.9.1. Company Overview
        • 7.9.2. Financial Highlights
        • 7.9.3. Product Portfolio
        • 7.9.4. SWOT Analysis
        • 7.9.5. Key Strategies and Developments
      • 7.10. Epigenomics AG
        • 7.10.1. Company Overview
        • 7.10.2. Financial Highlights
        • 7.10.3. Product Portfolio
        • 7.10.4. SWOT Analysis
        • 7.10.5. Key Strategies and Developments
      • 7.11. GlycoZym
        • 7.11.1. Company Overview
        • 7.11.2. Financial Highlights
        • 7.11.3. Product Portfolio
        • 7.11.4. SWOT Analysis
        • 7.11.5. Key Strategies and Developments
      • 7.12. HalioDx SAS
        • 7.12.1. Company Overview
        • 7.12.2. Financial Highlights
        • 7.12.3. Product Portfolio
        • 7.12.4. SWOT Analysis
        • 7.12.5. Key Strategies and Developments
      • 7.13. Louisville Bioscience Inc.
        • 7.13.1. Company Overview
        • 7.13.2. Financial Highlights
        • 7.13.3. Product Portfolio
        • 7.13.4. SWOT Analysis
        • 7.13.5. Key Strategies and Developments
      • 7.14. May
        • 7.14.1. Company Overview
        • 7.14.2. Financial Highlights
        • 7.14.3. Product Portfolio
        • 7.14.4. SWOT Analysis
        • 7.14.5. Key Strategies and Developments
    • 8. Assumptions and Acronyms
    • 9. Research Methodology
    • 10. Contact
    • Advpharma Inc
    • AIT Austrian Institute of Technology GmbH
    • Courtagen Life Sciences Inc
    • DiagnoCure Inc. (Inactive)
    • BioMark Diagnostics Inc.
    • BioMarker Strategies LLC
    • Emory University
    • Epigenomics AG
    • GlycoZym
    • HalioDx SAS
    • Louisville Bioscience Inc.
    • May
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Lung Cancer Diagnostic Tests Market
  • 41429
  • Aug 2022
    • ★★★★★
      ★★★★★
    • (18)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore